IL205284A - Monoclonal antibodies against activated protein c, a pharmaceutical composition comprising the same and use thereof - Google Patents

Monoclonal antibodies against activated protein c, a pharmaceutical composition comprising the same and use thereof

Info

Publication number
IL205284A
IL205284A IL205284A IL20528410A IL205284A IL 205284 A IL205284 A IL 205284A IL 205284 A IL205284 A IL 205284A IL 20528410 A IL20528410 A IL 20528410A IL 205284 A IL205284 A IL 205284A
Authority
IL
Israel
Prior art keywords
antibody
protein
apc
medicament
manufacture
Prior art date
Application number
IL205284A
Other languages
English (en)
Hebrew (he)
Other versions
IL205284A0 (en
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Publication of IL205284A0 publication Critical patent/IL205284A0/en
Publication of IL205284A publication Critical patent/IL205284A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
IL205284A 2007-10-26 2010-04-22 Monoclonal antibodies against activated protein c, a pharmaceutical composition comprising the same and use thereof IL205284A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Publications (2)

Publication Number Publication Date
IL205284A0 IL205284A0 (en) 2010-12-30
IL205284A true IL205284A (en) 2014-06-30

Family

ID=40289112

Family Applications (2)

Application Number Title Priority Date Filing Date
IL205284A IL205284A (en) 2007-10-26 2010-04-22 Monoclonal antibodies against activated protein c, a pharmaceutical composition comprising the same and use thereof
IL220622A IL220622A0 (en) 2007-10-26 2012-06-24 Monoclonal antibodies against activated and unactivated protein c

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL220622A IL220622A0 (en) 2007-10-26 2012-06-24 Monoclonal antibodies against activated and unactivated protein c

Country Status (13)

Country Link
US (3) US8153766B2 (https=)
EP (1) EP2205638B1 (https=)
JP (3) JP2011500843A (https=)
KR (2) KR20150092358A (https=)
CN (3) CN105153308A (https=)
AU (1) AU2008316661B2 (https=)
BR (1) BRPI0818865A2 (https=)
CA (1) CA2703738C (https=)
IL (2) IL205284A (https=)
MX (1) MX2010004615A (https=)
RU (2) RU2539729C2 (https=)
WO (1) WO2009055669A2 (https=)
ZA (1) ZA201105704B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201700360VA (en) * 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
CN104812402A (zh) * 2012-11-29 2015-07-29 拜尔健康护理有限责任公司 针对活化蛋白C (aPC)的单克隆抗体
HK1215174A1 (zh) * 2012-11-29 2016-08-19 Bayer Healthcare Llc 針對活化蛋白c的人源化單克隆抗體及其用途
WO2015041310A1 (ja) 2013-09-20 2015-03-26 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
WO2019009407A1 (ja) * 2017-07-07 2019-01-10 第一三共株式会社 抗プロテインｃ抗体
WO2019016392A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag HUMAN ANTIBODIES BINDING TO ROR2
EP3971572A1 (en) * 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
WO2020051277A1 (en) * 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
JP7248788B2 (ja) * 2018-10-18 2023-03-29 オクラホマ メディカル リサーチ ファウンデーション 疾患活動性を特徴付ける全身性エリテマトーデス（ｓｌｅ）疾患活動性免疫指標のバイオマーカー
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CA3245346A1 (en) * 2022-03-04 2023-09-07 Coagulant Therapeutics Corporation Camelid antibodies directed against activated protein C and their uses
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
ATE464374T1 (de) * 2000-10-02 2010-04-15 Oklahoma Med Res Found Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Also Published As

Publication number Publication date
IL205284A0 (en) 2010-12-30
AU2008316661A1 (en) 2009-04-30
JP2013049694A (ja) 2013-03-14
CA2703738A1 (en) 2009-04-30
KR101856210B1 (ko) 2018-05-09
JP6117741B2 (ja) 2017-04-19
ZA201105704B (en) 2014-05-28
JP2011500843A (ja) 2011-01-06
RU2012150953A (ru) 2014-06-10
US9127072B2 (en) 2015-09-08
US20120164150A1 (en) 2012-06-28
CN103232541A (zh) 2013-08-07
IL220622A0 (en) 2012-08-30
KR20150092358A (ko) 2015-08-12
CN105153308A (zh) 2015-12-16
AU2008316661B2 (en) 2013-05-23
WO2009055669A2 (en) 2009-04-30
RU2539729C2 (ru) 2015-01-27
US8153766B2 (en) 2012-04-10
CN101918453A (zh) 2010-12-15
CA2703738C (en) 2018-02-27
WO2009055669A3 (en) 2009-09-03
EP2205638A2 (en) 2010-07-14
KR20100116166A (ko) 2010-10-29
EP2205638B1 (en) 2017-03-01
MX2010004615A (es) 2010-07-06
US20090110683A1 (en) 2009-04-30
RU2010121148A (ru) 2011-12-10
BRPI0818865A2 (pt) 2015-05-05
US20150344588A1 (en) 2015-12-03
JP2014237651A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
US8153766B2 (en) Monoclonal antibodies against activated protein C
JP2024170616A (ja) Ｍａｓｐ－２依存性の補体活性化を阻害するための組成物
CN109715209B (zh) 用于治疗各种疾病和病症的抑制masp-3的组合物和方法
JP2025108730A (ja) 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法
US20160166660A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
CA3019851A1 (en) Method of treating atherosclerosis
US11597777B2 (en) Antibodies for the prevention or the treatment of bleeding episodes
JP2026062897A (ja) 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法
AU2016203760B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2015200348B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2013202464B2 (en) Monoclonal antibodies against activated and unactivated protein c
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c
US20250163181A1 (en) Anti-prothrombin antibodies targeting the open form of prothrombin
HK40116756A (zh) 用於治疗和/或预防静脉闭塞性病的方法
HK40114300A (zh) 用於治疗和/或预防弥漫性肺泡出血的方法

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed